接受静脉-静脉体外膜氧合治疗的COVID-19患者死亡相关预后因素:系统评价与Meta分析
该系统评价与Meta分析检索MEDLINE和Embase(2019年12月1日至2022年4月14日),纳入42项观察性队列研究、共17449例因COVID-19相关ARDS接受静脉-静脉ECMO的成年患者,评估插管前预后因素与院内死亡的关系。与死亡风险升高相关且证据确定性为中等或高的因素包括:高龄(aHR 2.27,95%CI 1.63-3.16)、男性(uOR 1.34,1.20-1.49)、慢性肺病(aHR 1.55,1.20-2.00)、症状持续时间更长(均数差1.51天,0.36-2.65)、有创机械通气时间更长(uOR 1.94,1.40-2.67)、动脉血二氧化碳分压更高(均数差4.04 mm Hg,1.64-6.44)、驱动压更高(aHR 2.36,1.40-3.97)以及ECMO经验较少(aOR 2.27,1.28-4.05)。作者认为这些因素应纳入评估患者是否接受静脉-静脉ECMO治疗时的风险分层框架。
要点
- 高龄与死亡风险升高相关:aHR 2.27(95%CI 1.63-3.16),证据确定性中等或高。
- 插管前驱动压更高与死亡风险升高相关:aHR 2.36(95%CI 1.40-3.97),提示肺损伤性通气的影响。
- 有创机械通气时间更长(uOR 1.94,95%CI 1.40-2.67)和症状持续时间更长(均数差1.51天,95%CI 0.36-2.65)与死亡风险升高相关。
- ECMO经验较少的中心死亡风险更高:aOR 2.27(95%CI 1.28-4.05)。
- 男性(uOR 1.34,95%CI 1.20-1.49)、慢性肺病(aHR 1.55,95%CI 1.20-2.00)、动脉血二氧化碳分压更高(均数差4.04 mm Hg,95%CI 1.64-6.44)也与死亡风险升高相关。
适用人群与场景
- 因COVID-19相关急性呼吸窘迫综合征需要静脉-静脉ECMO治疗的成年患者。
- 纳入评估插管前预后因素与院内死亡关系的研究; randomised controlled trials和观察性研究。
研究设计与关键结果
- 研究类型:系统评价与Meta分析;检索MEDLINE和Embase(2019年12月1日至2022年4月14日),最终纳入42项观察性队列研究、共17449例患者。
- 高龄与死亡风险升高相关:aHR 2.27(95%CI 1.63-3.16),证据确定性中等或高。
- 男性与死亡风险升高相关:uOR 1.34(95%CI 1.20-1.49),证据确定性中等或高。
- 慢性肺病与死亡风险升高相关:aHR 1.55(95%CI 1.20-2.00),证据确定性中等或高。
- 症状持续时间更长与死亡风险升高相关:均数差1.51天(95%CI 0.36-2.65),证据确定性中等或高。
- 有创机械通气时间更长与死亡风险升高相关:uOR 1.94(95%CI 1.40-2.67),证据确定性中等或高。
- 动脉血二氧化碳分压更高与死亡风险升高相关:均数差4.04 mm Hg(95%CI 1.64-6.44),证据确定性中等或高。
- 驱动压更高与死亡风险升高相关:aHR 2.36(95%CI 1.40-3.97),证据确定性中等或高;ECMO经验较少与死亡风险升高相关:aOR 2.27(95%CI 1.28-4.05)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入42项观察性队列研究;使用Quality in Prognosis Studies工具评估偏倚风险,使用GRADE方法评估证据确定性。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,所识别的预后因素突显了患者选择的重要性、肺损伤性通气的影响,以及在COVID-19相关ARDS的ECMO治疗中进一步集中化和协作的潜在机会。
- 作者认为,在评估患者是否接受静脉-静脉ECMO治疗时,应将这些因素作为风险分层框架的一部分仔细考虑。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Venovenous extracorporeal membrane oxygenation (ECMO) can be considered for patients with COVID-19-associated acute respiratory distress syndrome (ARDS) who continue to deteriorate despite evidence-based therapies and lung-protective ventilation. The Extracorporeal Life Support Organization has emphasised the importance of patient selection; however, to better inform these decisions, a comprehensive and evidence-based understanding of the risk factors associated with poor outcomes is necessary. We aimed to summarise the association between pre-cannulation prognostic factors and risk of mortality in adult patients requiring venovenous ECMO for the treatment of COVID-19.
METHODS: In this systematic review and meta-analysis, we searched MEDLINE and Embase from Dec 1, 2019, to April 14, 2022, for randomised controlled trials and observational studies involving adult patients who required ECMO for COVID-19-associated ARDS and for whom pre-cannulation prognostic factors associated with in-hospital mortality were evaluated. We conducted separate meta-analyses of unadjusted and adjusted odds ratios (uORs), adjusted hazard ratios (aHRs), and mean differences, and excluded studies if these data could not be extracted. We assessed the risk of bias using the Quality in Prognosis Studies tool and certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation approach. Our protocol was registered with the Open Science Framework registry, osf.io/6gcy2.
FINDINGS: Our search identified 2888 studies, of which 42 observational cohort studies involving 17 449 patients were included. Factors that had moderate or high certainty of association with increased mortality included patient factors, such as older age (adjusted hazard ratio [aHR] 2·27 [95% CI 1·63-3·16]), male sex (unadjusted odds ratio [uOR] 1·34 [1·20-1·49]), and chronic lung disease (aHR 1·55 [1·20-2·00]); pre-cannulation disease factors, such as longer duration of symptoms (mean difference 1·51 days [95% CI 0·36-2·65]), longer duration of invasive mechanical ventilation (uOR 1·94 [1·40-2·67]), higher partial pressure of arterial carbon dioxide (mean difference 4·04 mm Hg [1·64-6·44]), and higher driving pressure (aHR 2·36 [1·40-3·97]); and centre factors, such as less previous experience with ECMO (aOR 2·27 [1·28-4·05].
INTERPRETATION: The prognostic factors identified highlight the importance of patient selection, the effect of injurious lung ventilation, and the potential opportunity for greater centralisation and collaboration in the use of ECMO for the treatment of COVID-19-associated ARDS. These factors should be carefully considered as part of a risk stratification framework when evaluating a patient for potential treatment with venovenous ECMO.
参考来源
- Tran A, Fernando SM, Rochwerg B, et al. Prognostic factors associated with mortality among patients receiving venovenous extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. Lancet Respir Med. 2022. PMID: 36228638. doi:10.1016/S2213-2600(22)00296-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。